Gamma glutamyl transpeptidase as a prognostic biomarker in hepatocellular cancer patients especially with >5 cm tumors, treated by liver transplantation

Basit Öğe Kaydı
dc.authoridSAHIN, TEVFIK TOLGA/0000-0002-9132-6115
dc.authoridGozukara Bag, Harika Gozde/0000-0003-1208-4072
dc.authoridince, volkan/0000-0002-0714-490X
dc.authoridBASKIRAN, ADIL/0000-0002-7536-1631
dc.authoridErsan, Veysel/0000-0002-1510-0288
dc.authoridYilmaz, Sezai/0000-0002-8044-0297
dc.authoridKoc, Cemalettin/0000-0002-5676-6772
dc.authorwosidSAHIN, TEVFIK TOLGA/AAA-9648-2021
dc.authorwosidGozukara Bag, Harika Gozde/ABG-7588-2020
dc.authorwosidince, volkan/M-7325-2017
dc.authorwosidBASKIRAN, ADIL/ABI-2356-2020
dc.authorwosidErsan, Veysel/AAB-9595-2020
dc.authorwosidYilmaz, Sezai/ABI-2323-2020
dc.authorwosidKoc, Cemalettin/B-6430-2018
dc.contributor.authorInce, Volkan
dc.contributor.authorCarr, Brian I.
dc.contributor.authorBag, Harika Gozukara
dc.contributor.authorKoc, Cemalettin
dc.contributor.authorUsta, Sertac
dc.contributor.authorErsan, Veysel
dc.contributor.authorBaskiran, Adil
dc.date.accessioned2024-08-04T20:48:43Z
dc.date.available2024-08-04T20:48:43Z
dc.date.issued2020
dc.departmentİnönü Üniversitesien_US
dc.description.abstractBackground Serum AFP levels are typically elevated in less than 50% of hepatocellular cancer (HCC) patients. Gamma-glutamyl transpeptidase (GGT) levels have been suggested to be a potentially useful HCC biomarker. Aims To assess in a cohort of prospectively evaluated HCC patients who underwent liver transplant and whose survival was known; the occurrence, prognosis, and clinical characteristics of patients with elevated serum GGT levels. Results Serum GGT levels were found to be elevated in a higher proportion in patients with either small or large HCC than alpha-fetoprotein (AFP) levels, and were significantly related to prognosis in patients with large size HCCs. There was no clear correlation between GGT and AFP levels, likely reflecting different HCC characteristics or HCC cell lineages associated with these two markers. Furthermore, elevated GGT was found in 24% of low-AFP patients with small tumors and 46% with large tumors. Elevated GGT levels were also significantly associated with microvascular invasion and tumor diameter. Conclusions Elevated serum GGT levels were associated with HCC size and worse survival, and were unrelated to AFP levels. GGT may be a useful prognostic tumor marker, especially for low-AFP HCC patients.en_US
dc.identifier.doi10.1177/1724600820921869
dc.identifier.endpage95en_US
dc.identifier.issn0393-6155
dc.identifier.issn1724-6008
dc.identifier.issue2en_US
dc.identifier.pmid32436751en_US
dc.identifier.scopus2-s2.0-85087466342en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage91en_US
dc.identifier.urihttps://doi.org/10.1177/1724600820921869
dc.identifier.urihttps://hdl.handle.net/11616/99397
dc.identifier.volume35en_US
dc.identifier.wosWOS:000544689400010en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSage Publications Ltden_US
dc.relation.ispartofInternational Journal of Biological Markersen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectHepatocellular carcinomaen_US
dc.subjectGGTen_US
dc.subjectalpha-fetoproteinen_US
dc.subjectsurvivalen_US
dc.titleGamma glutamyl transpeptidase as a prognostic biomarker in hepatocellular cancer patients especially with >5 cm tumors, treated by liver transplantationen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu